PROTEINA Co., Ltd.

3:00 PM - 3:15 PM (PDT), Monday, June 13, 2022
As next-generation sequencing has shown, high-precision molecular diagnostics have great potential for personalized medicine, revolutionizing the way diseases such as cancer are treated. Although protein-protein interactions (PPIs) embody the flow of cellular information, determining the physical amounts of PPI complexes and profiling PPI networks have remained elusive in the field of precision medicine.
Our “Single-Molecule Co-Immunoprecipitation” platform permits the extraction of PPI complexes from various types of clinical specimens. Our platform tech can detect changes in the populations of specific PPI complexes occurring in only a few thousand cells, a new capability that provides novel target engagement assays for drugs and crucial information on the determination of correct doses for clinical development. Moreover, the quantitativeness of our tech allows direct integration of all data to generate “big data” of PPI metrics that unfold new opportunities in precision medicine.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2015
Main Therapeutic Focus:
Lead Product in Development:
PPI biomarker panel for the BCL2-family network proteins regulating cell apoptosis
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
photo
CTO
Proteina Co., Ltd.